Yarrow Bioscience Launches Underwritten Public Offering to Support Autoimmune Thyroid Disease Pipeline
Yarrow Bioscience, Inc., a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, has announced the commencement of an underwritten public offering of its securities. The proposed financing is designed to provide additional capital to support the company’s research and development activities and broader corporate operations as it advances its therapeutic pipeline.
Under the proposed offering, Yarrow Bioscience plans to sell shares of its common stock to investors. Certain investors may instead elect to purchase pre-funded warrants that can be exercised to acquire shares of Yarrow’s common stock. The company expects the financing to provide resources that can be directed toward the continued development of its programs targeting autoimmune thyroid diseases, an area in which the company is seeking to develop new treatment approaches.
Yarrow’s announcement represents another step in its efforts to strengthen its financial position while progressing its clinical-stage biotechnology programs. As a development-stage company, continued access to capital is an important component of advancing research, conducting clinical and preclinical activities, maintaining corporate operations and preparing potential therapies for future development milestones.
The size, pricing and final terms of the proposed offering have not yet been determined. Yarrow stated that the public offering remains subject to market conditions and other customary closing conditions, meaning there can be no assurance regarding whether or when the transaction will be completed. The company also noted that the actual size and terms of the offering could differ from the preliminary expectations outlined in the announcement.
Common Stock and Pre-Funded Warrants Offered
The securities being offered are being sold directly by Yarrow Bioscience. The company intends to provide investors with the option, in certain circumstances, to purchase either common stock or pre-funded warrants.
Pre-funded warrants are securities that generally allow an investor to acquire common shares by paying a nominal exercise price after the initial transaction. Their inclusion in the offering can provide additional flexibility for investors that may have limitations on the number of common shares they can beneficially own immediately following the transaction.
In addition to the securities included in the base offering, Yarrow expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the transaction. Any shares sold pursuant to this option would be offered at the public offering price, less applicable underwriting discounts and commissions.
The underwriter option could provide Yarrow with an opportunity to raise additional gross proceeds if the underwriters exercise the option in whole or in part. However, the company has not indicated that the option will necessarily be exercised, and the final amount of securities sold will depend on market conditions and investor demand.
Proceeds to Support Research and Development
Yarrow Bioscience expects to use the net proceeds from the offering primarily to support research and development expenses associated with its pipeline. The company is focused on developing therapies for autoimmune thyroid diseases, and the additional financing is expected to help sustain its ongoing development activities.
The company also plans to use a portion of the proceeds for general corporate purposes. These purposes may include working capital, capital expenditures and other operating expenses associated with running the business.
For a clinical-stage biotechnology company, financing can play a particularly important role because substantial resources are typically required to advance drug candidates through research and development. Expenses can include laboratory research, manufacturing activities, clinical trial preparation and execution, regulatory activities, personnel, technology infrastructure and other operational requirements.
By securing additional capital through the proposed public offering, Yarrow aims to maintain financial flexibility while continuing to invest in its pipeline. The company has not specified how much of the expected proceeds will be allocated to individual programs or activities, and the ultimate use of funds will depend on the company’s development priorities and business needs.
Investment Banks Leading the Offering
Jefferies, TD Cowen and Guggenheim Securities are serving as joint book-running managers for the proposed public offering. LifeSci Capital is acting as lead manager.
The involvement of multiple investment banks reflects the syndicated structure of the transaction, with the financial institutions supporting the marketing, distribution and execution of the proposed securities offering.
The underwriting process will ultimately determine the pricing and number of securities sold, subject to investor demand and prevailing market conditions. Until the offering is priced and completed, the total proceeds available to Yarrow cannot be determined.
Registration Statement Declared Effective
Yarrow’s proposed offering is being conducted under a shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission (SEC). The registration statement was declared effective by the SEC on August 19, 2026.
A shelf registration allows an eligible company to register securities for potential future offerings, providing greater flexibility in accessing capital markets when financing opportunities arise. Yarrow is now utilizing that registration framework for the proposed underwritten public offering.
The company emphasized that the securities will be offered only through a written prospectus, including a prospectus supplement, that forms part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus are expected to be filed with the SEC in connection with the transaction.
Investors will be able to review the relevant offering documents through the SEC’s public filing system once they become available. The documents are expected to provide additional information concerning the number of securities being offered, the proposed public offering price, underwriting arrangements, potential dilution and other terms of the transaction.
Financing Comes as Yarrow Advances Its Biotechnology Strategy
The financing announcement comes as Yarrow continues to operate as a clinical-stage biotechnology company focused on autoimmune thyroid diseases. Developing treatments for autoimmune conditions can require substantial investment over an extended period, particularly as programs progress through increasingly complex stages of development.
Autoimmune thyroid diseases occur when the immune system mistakenly targets components of the thyroid or related biological pathways. Depending on the specific condition, patients can experience significant effects on metabolism, energy, cardiovascular health and overall quality of life. Existing therapies address important aspects of thyroid disease, but biotechnology companies continue to investigate approaches intended to address underlying disease mechanisms.
Yarrow’s stated focus on transformative therapies places continued research and development at the center of its corporate strategy. The proposed financing could therefore provide the company with additional resources to maintain and potentially expand its development activities.
At this stage, however, the company has not disclosed a final financing amount or provided specific guidance on how the proceeds will be distributed among individual programs. Investors will likely look to the final prospectus supplement and subsequent corporate disclosures for additional information regarding the company’s cash position, development priorities and expected financial runway.
Offering Remains Subject to Market Conditions
Yarrow stressed that the proposed public offering is not yet a completed financing. The transaction remains subject to market and other conditions, and there is no guarantee that the offering will close.
This distinction is important because the final terms of a public offering can change between the initial announcement and pricing. Factors such as investor demand, biotechnology market conditions, the company’s share price and broader financial-market conditions can influence the final transaction.
If completed, the offering would result in the issuance of additional securities by Yarrow and could therefore affect the ownership interests of existing shareholders. The final impact on shareholders will depend on the number and type of securities ultimately sold and the applicable offering price.
Yarrow’s expected 30-day underwriter option also introduces the possibility of additional common shares being sold beyond the base offering. If fully exercised, the option could increase the amount of capital raised while also increasing the number of outstanding shares.
Prospectus Availability and Investor Information
Once filed, the preliminary prospectus supplement and accompanying prospectus will be available through the SEC. Copies may also be obtained from the participating investment banks involved in the offering.
Jefferies is providing prospectus materials through its Equity Syndicate Prospectus Department. TD Securities is making documents available through Broadridge Financial Solutions, while Guggenheim Securities and LifeSci Capital will also provide access to the relevant materials through their respective offices and designated contacts.
The prospectus documents will contain the formal terms of the transaction and should be reviewed by prospective investors before making any investment decision.
Yarrow also made clear that its announcement does not constitute an offer to sell securities or a solicitation of an offer to purchase securities. The securities may not be sold in any jurisdiction where such an offer, solicitation or sale would be unlawful before the securities have been registered or qualified under applicable securities laws.
The proposed public offering provides Yarrow Bioscience with a potential source of additional funding as it continues to advance its clinical-stage biotechnology strategy. If successfully completed, the financing is expected to support research and development activities across the company’s pipeline while also providing capital for working capital, capital expenditures and other general corporate needs.
The final size, pricing and terms of the offering remain subject to market conditions and the underwriting process. Investors will receive further details through the preliminary and final prospectus documents filed with the SEC.
For Yarrow, the proposed financing underscores the company’s continued focus on investing in its autoimmune thyroid disease pipeline. As the company works to advance its development programs, access to additional capital could help support research and operational activities needed to pursue future clinical and regulatory milestones.
About Yarrow Bioscience
Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, a potential first-in-class anti-thyroid stimulating hormone receptor monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves’ disease and thyroid eye disease.